A Phase 1/2 interventional study of Tisotumab Vedotin and Bevacizumab in Cervical Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Terminated at 71 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Uterine Cervical Neoplasms by Pfizer — 3 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Neoplasms · Pfizer.
Among the 17 studies in Uterine Cervical Neoplasms by Pfizer, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 1/2, and was the 7th registered.
2,366 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →3 of the 17 studies in Uterine Cervical Neoplasms by Pfizer are open now, in 8 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Puerto Rico
Ages 18+ · Women only
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 1 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 122 across the 16 interventional studies, 0 across the 1 observational. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen, a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
1 of the studies in Uterine Cervical Neoplasms by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Uterine Cervical Neoplasms by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.
The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
The dose escalation part will occur in participants with cervical cancer who have progressed during or after standard of care therapy and who are intolerant or ineligible to receive standard of care treatments. Arm A will be conducted by escalating doses of both tisotumab vedotin and bevacizumab. Dose escalations of the tisotumab vedotin + pembrolizumab and tisotumab vedotin + carboplatin combinations (Arms B and C, respectively) will be conducted by combining fixed doses of either pembrolizumab or carboplatin with increasing doses of tisotumab vedotin.
The dose expansion part of this study (Arms D through H) will be conducted in 2 populations: participants with cervical cancer who have not received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D, E, and H) and participants with cervical cancer who have progressed on or after at least 1 but no more than 2 prior systemic therapies (Arms F and G).
Participants enrolled to Arms D, E, F and H will receive the RP2D of tisotumab vedotin established in the dose escalation part. Participants enrolled to Arm G will receive tisotumab vedotin weekly (at a dose lower than subjects in all other Arms) for three weeks and 1 week off (28-day treatment cycle).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has clinically significant bleeding issues or risks
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients
Drug: Tisotumab Vedotin · Drug: Bevacizumab
Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
Drug: Tisotumab Vedotin · Drug: Pembrolizumab
Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients
Drug: Tisotumab Vedotin · Drug: Carboplatin
Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients
Drug: Tisotumab Vedotin · Drug: Carboplatin
Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients
Drug: Tisotumab Vedotin · Drug: Pembrolizumab
Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
Drug: Tisotumab Vedotin · Drug: Pembrolizumab
Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.
Drug: Tisotumab Vedotin
Dose expansion: Tisotumab vedotin in combination with pembrolizumab and carboplatin with or without bevacizumab once every three weeks in previously untreated patients
Drug: Tisotumab Vedotin · Drug: Bevacizumab · Drug: Pembrolizumab · Drug: Carboplatin
Given into the vein (IV)
Also known as: TIVDAK
Given via IV
Also known as: Avastin
Given via IV
Also known as: KEYTRUDA®
Given via IV
Also known as: Paraplatin
Dose escalation: Dose Limiting Toxicities (DLTs)
To establish the MTD and RP2D of tisotumab vedotin in combination
Time frame: DLTs will be identified during the first treatment cycle (21 day cycles)
Dose expansion: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Objective response is defined as confirmed partial response (PR) or complete response (CR)
Time frame: approximately 2 years
Number of adverse events (AEs)
Any untoward medical occurrence in a clinical trial participant whether or not considered related to the medicinal product.
Time frame: up to 2 years
Dose escalation: ORR per RECIST v1.1
Objective response is defined as confirmed PR or CR.
Time frame: approximately 2 years
Duration of Response (DOR) per RECIST v1.1 by investigator assessment
Will be calculated from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease (PD) or death.
Time frame: approximately 2 years
Time to Response (TTR) per RECIST v1.1 by investigator assessment
Will be calculated from the date of the first dose to the date of the initial documentation of response (CR or PR).
Time frame: approximately 2 years
Progression free survival (PFS) per RECIST v1.1 by investigator assessment
The time from the date of the first trial drug administration to the date of the first documented disease progression or death due to any cause.
Time frame: approximately 2 years
Overall Survival (OS)
The time from the date of the first trial drug administration to the date of death due to any cause.
Time frame: approximately 2 years
Maximum concentration (Cmax) (All Arms except G)
Pharmacokinetic (PK) parameter
Time frame: Up to 42 days
Cmax (Arm G only)
PK parameter
Time frame: Up to 2 years
Trough Concentration (Ctrough) (All Arms)
PK parameter
Time frame: Up to 2 years
Area under the concentration-time curve (AUC) (All Arms except G)
PK parameter
Time frame: Through 21 days after first dose
AUC (Arm G only)
PK parameter
Time frame: Through 8 days after first dose
Anti-drug antibodies (ADAs)
Time frame: Up to 2 years
Ran from Feb 2019 to primary completion in Mar 2026, 84 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tisotumab vedotin
Seagen, a wholly owned subsidiary of Pfizer →